# SURVEILLANCE TESTING SERVICES AGREEMENT (Non-Governmental Entity Arrangement)

THIS SURVEILLANCE TESTING SERVICES AGREEMENT ("Agreement"), effective on the day of \_\_\_\_\_\_, 20\_\_\_\_ ("Effective Date"), is by and between Wichita State University, a Kansas public institution ("Lab") and \_\_\_\_\_\_, ("Testing Entity"), referred individually as "party" and collectively as "parties."

WHEREAS, Lab is a clinical laboratory certified under the Clinical Laboratory Improvement Act ("CLIA") that provides laboratory services; and

WHEREAS, Testing Entity desires to engage Lab to provide certain services as enumerated herein, and Lab desires to provide such services, all upon the terms, conditions, and mutual promises hereinafter contained.

NOW, THEREFORE, in consideration of the premises above and the mutual promises herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. <u>Term</u>. The term of this Agreement shall be one (1) year commencing on the Effective Date unless terminated earlier as provided herein ("Term"). This Agreement will automatically renew for successive one (1) year terms unless either party provides a written notice of non-renewal to the other party at least thirty (30) days prior to the end of the then-current Term.

2. <u>Lab Services</u>. Lab shall provide processing of specimens obtained by Testing Entity for SARS CoV-2 ("Services") for employees, contractors, and other persons designated by Testing Entity ("Designated Persons"). Lab is not responsible for obtaining the specimens from Designated Persons. In connection with the Services and subject to availability, Lab shall provide Testing Entity specimen collection supplies ("Supplies") to enable Testing Entity to collect, or coordinate the collection of, specimens from Designated Persons. Designated Persons and Testing Entity, if authorized, will receive a link to a secure website to view and/or print the test results when the test results are available. Lab shall use reasonable efforts to report test results to Designated Persons and Testing Entity, if authorized, within the time allotments identified in <u>Exhibit A</u>. Results will not be reported to Testing Entity or any third-party designated by Testing Entity unless such Designated Person has authorized the release of test results to such party and such release is provided by Testing Entity to Lab.

3. <u>Specimen Drop-off</u>. Testing Entity shall be responsible for dropping off all specimens at the Lab in accordance with the drop-off protocol established by Lab. Lab will only accept specimens collected using the Supplies provided by Lab. Testing Entity may avail itself of any of the drop-off methods listed in Appendix A. Notwithstanding the foregoing, Testing Entity acknowledges and agrees that in no event will Lab guarantee that test results will be reported within the time allotments set forth in Exhibit A. Lab will notify Testing Entity of any specimens dropped off at the Lab that are deemed not suitable for processing.

4. <u>Reporting</u>. Lab shall be responsible for reporting to applicable federal or state health authorities regarding SARS CoV-2 test results. Testing Entity shall provide Lab with all necessary Designated Persons demographic information to enable Lab to meet such reporting obligations.

5. <u>Testing Entity Responsibilities</u>. Testing Entity will be responsible for the following:

a. obtaining and utilizing only Supplies provided by Lab for the collection of any specimen;

b. providing all necessary information for any specimen dropped off at the Lab, including the individual's name, date of birth, telephone number, email address and county of residence and such other demographic information as may be necessary to enable Lab to meet applicable reporting obligations;

c. notifying Lab at least twenty-four (24) hours in advance of any anticipated delivery of over 500 specimens;

d. ensuring that all laboratory tests for Designated Persons are ordered by appropriately authorized healthcare providers and that a copy of the order is provided to Lab (Lab may accept a standing order for Testing Entity from an authorized healthcare provider, if applicable);

e. ensuring that appropriately qualified, trained and supervised staff perform the collection of specimens using the Supplies provided by Lab and that such specimens are collected in accordance with the protocols established by Lab;

f. confirming that all Designated Persons are properly registered through the Lab portal and that all handwritten information on any specimen is legibly written in English;

g. packaging specimens in accordance with specifications established by Lab; and

h. timely, same day submission of specimens to the Lab in accordance with the protocols established by Lab.

Testing Entity acknowledges that valid laboratory results are dependent upon proper specimen collection and handling before arrival of the sample at the Lab. Specimen collection will vary depending on test type. Instructions for properly collecting the specimen are included in the Supplies provided by Lab.

6. <u>Qualifications/Compliance with Laws/Regulations, Rules/Standards</u>. At all times during the Term, Lab shall comply with all applicable laws, rules and regulations of the United States, the State of Kansas, and any other applicable states or governmental agencies in the performance of Services hereunder. Lab also agrees to evaluate existing and forthcoming Centers for Diseases Control and Prevention guidelines, as they become available, and incorporate them into the process and protocols as deemed appropriate by Lab.

7. <u>Compensation</u>.

a. Testing Entity shall compensate Lab pursuant to the fee schedule attached hereto as <u>Exhibit B</u>. Testing Entity shall remit payment to Lab within thirty (30) days of the date of a Lab invoice for Services rendered hereunder. Should payment not be received within those thirty (30) days, Lab reserves the right to assess a one and one-half percent (1.5%) service charge on any outstanding balance. If payment is not received in full within sixty (60) days of the date of the invoice Lab may, at its option, charge an additional two percent (2%) service charge on any outstanding balance. Testing Entity shall be responsible for all collection or legal fees necessitated by lateness or default in payment.

b. The parties acknowledge that the compensation payable hereunder is intended to compensate Lab for the services provided by Lab to Testing Entity and is not dependent upon the volume or value of any referral of patient by Testing Entity to Lab. Nothing herein shall be intended or implied to require the referral of any patient to Lab.

c. In the event that either party desires to submit claims to a third-party payor, including but not limited to government payors such as Medicare or Medicaid, the parties will determine the appropriate billing arrangement to ensure that no payor is double billed and that all applicable billing rules are followed.

8. <u>Cooperation in the Event of a Claim</u>. In the event that Testing Entity becomes aware of any alleged injury arising out of or relating to Services provided under this Agreement, Testing Entity shall give the Lab written notice within fifteen (15) days containing the particulars sufficient to identify the name and address of the allegedly injured person, place and circumstances of the alleged incident, and the names and addresses of the available witnesses. Additionally, Lab shall be entitled to receive notice of any lawsuit filed or written demand of a claim against Testing Entity related to the performance of services provided under this Agreement, within ten (10) days of receipt by Testing Entity of notice of such claim or lawsuit.

a. Each of the parties shall cooperate with each other in the conduct of suits and in enforcing any right of contribution or indemnity against any person or organization who may be liable to any of the parties because of injury with respect to which insurance is afforded, and shall attend the hearings and trials and assist in securing evidence and obtaining the attendance of witnesses as is reasonably necessary.

b. In the event any party is entitled to indemnity pursuant to Section 9, the party entitled to indemnity shall, to the extent allowed by law, tender all defense responsibilities to the indemnifying party and its insurer(s), provided, however, the indemnifying party shall cause the party to be indemnified to be informed of the progress of any claim or litigation and the defense thereof and provided, further, that in the event such claim or action being defended by the indemnifying party or its insurer seeks monetary damages from the party to be indemnified which are not covered by or are in excess of the limits of the indemnifying party's professional liability insurance coverage, the party to be indemnified shall have the right at any time at its election (i) to assume its own defense at its own cost in which case the obligation to indemnify will be cancelled; or (ii) to participate in the defense of such claim in an advisory, non-decision making capacity in which case the obligation to indemnify will remain. Nothing herein shall be construed, however, as requiring the indemnifying party to defend, indemnify, or hold the party to be indemnified harmless from its own negligence or that of its employees.

9. Indemnification. To the extent allowed by law, each party (each respectively an "Indemnitor") shall indemnify, defend and hold harmless the other party and the other party's respective affiliates, officers, directors, employees, contractors, and agents from and against any and all claims, suits, actions, proceedings, liabilities, damages, costs or expenses, including attorney fees and court costs (each a "Claim") to the extent arising from (a) the breach of any warranty, representation or covenant in this Agreement and (b) the negligent acts or omissions or intentional misconduct by the Indemnitor or its officers, directors, employees, contractors, representatives or agents. The provisions of this section shall survive termination of this Agreement. Notwithstanding the foregoing, no provision of this Agreement will be given effect that attempts to require Lab to defend, hold harmless, or indemnify Testing Entity or any third party for any acts or omissions. The liability of Lab is defined under the Kansas Tort Claims Act (K.S.A. § 75-6101 et seq.).

### 10. <u>Termination</u>.

a. For Cause. This Agreement may be terminated by either party at any time in the event of a breach of or noncompliance with any covenant, term or condition of this Agreement after the non-breaching party has provided written notice of such breach or noncompliance and the same remains uncured for fifteen (15) business days subsequent to the giving of such notice.

b. For Convenience. Either party may terminate this Agreement without cause upon thirty (30) days' prior written notice to the other party.

11. <u>Confidential Information</u>. All terms set forth in the Agreement and information or data relating to the business or operations of any party to this Agreement acquired by any other party hereto in connection with this Agreement shall be treated as strictly confidential by the receiving party, and shall not, unless otherwise required by law, be disclosed by the receiving party without the prior written permission of the party hereto to whom the information in question relates. This provision shall survive termination of this Agreement.

12. <u>Privacy and Security Compliance</u>. The parties agree to maintain the privacy and security of any individually identifiable information received from or created for the other party in accordance with all relevant state and federal laws and regulations. This provision shall survive termination of this Agreement.

13. <u>Applicable Law</u>. The parties agree that the validity, interpretation, and enforcement of this Agreement shall be governed by the laws of the State of Kansas. Jurisdiction and venue of any suit in connection with this Agreement shall reside solely in the courts located in Sedgwick County, Kansas.

14. <u>Independent Contractor</u>. Lab's Services hereunder are to be rendered in the capacity of an independent contractor of Testing Entity. Neither party has authority to enter into contracts or assume any obligations for or on behalf of the other party or to make any warranties or representations for or on behalf of the other party.

15. <u>Assignment</u>. Neither party may assign its rights nor subcontract any of its obligations hereunder to a third party without the other party's advance written consent.

16. <u>Notices</u>. All notices, demands, requests, approvals, reports, instructions, consents or other communications (collectively "notices") which may be required or desired to be given by either Party to the other shall be **IN WRITING** and sent by certified mail or overnight traceable delivery and addressed as follows, unless any other person or address may be designated by notice from one Party to the other:

If to Wichita State University:	If to Testing Entity:
Attn: Molecular Diagnostic Lab Wichita State University 4174 S. Oliver, Bldg 174H Wichita KS 67210	Attn:

With a copy to (optional):

With a copy to:

Attn: General Counsel Wichita State University 1845 Fairmount Street Wichita, KS 67260-0205

17. <u>Entire Agreement; Amendment</u>. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, understandings and agreements. No amendment of this Agreement will have any force or effect unless such amendment specifically indicates it is a modification of this Agreement, is in writing and signed by authorized representatives of both parties.

18. <u>Severability</u>. If any provision of this Agreement is found to be invalid, illegal, or unenforceable by a court of competent jurisdiction, the validity, legality, and enforceability of the remaining portion of the provision and all other provisions shall not be affected or impaired.

19. <u>Waiver</u>. Any waiver shall be in writing and provided to all other Parties. Failure to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, shall not be deemed a waiver of any rights of any Party hereto.

20. <u>Arbitration, Damages, Warranties</u>. Notwithstanding any language to the contrary, no interpretation of this contract shall find that Lab has agreed to binding arbitration, or the payment of damages or penalties. Further, Lab does not agree to pay attorney fees, costs, or late payment charges beyond those available under the Kansas Prompt Payment Act (K.S.A. § 75-6403), and no provision will be given effect that attempts to exclude, modify, disclaim or otherwise attempt to limit any damages available to Lab at law, including but not limited to the implied warranties of merchantability and fitness for a particular purpose.

21. <u>Counterparts</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which when taken together shall constitute one and the same instrument. A copy, electronic version or facsimile of any such document shall be as effective as an original.

22. <u>Electronic Signatures</u>. The Parties agree that this Agreement may be signed with electronic signatures. Whenever either Party executes an electronic signature on this Agreement, it has the same validity and meaning as a handwritten signature and shall be legally binding equivalent. The Parties agree that neither Party will, at any time in the future, repudiate the meaning of an electronic signature or claim that an electronic signature is not legally binding.

23. <u>No Third-Party Beneficiaries</u>. It is the explicit intention of the parties hereto that no person or entity other than the parties hereto is or shall be entitled to bring any action to enforce any provision of this Agreement against either of the parties hereto, and that the covenants, undertakings, and agreements set forth in this Agreement shall be solely for the benefit of, and shall be enforceable only by, the parties hereto or their respective successors and assigns as permitted hereunder.

24. <u>Headings</u>. The section headings in this Agreement are for convenience only and shall not affect the construction of this Agreement.

25. <u>Force Majeure</u>. WSU shall not be liable to Testing Entity for any failure or delay caused by events beyond WSU's reasonable control, including, without limitation, a failure to furnish necessary information,

sabotage, failures or delays in transportation or communication, failures or substitutions of equipment, labor disputes, accidents, shortages of labor, fuel, raw materials, or equipment, technical failures, epidemics, or pandemics (including, but not limited to COVID-19 (in each case, a "Force Majeure Event"), provided WSU notifies Testing Entity as soon as possible of any Force Majeure Event and uses its reasonable best efforts to mitigate and remedy the adverse effects of such a Force Majeure Event. In the event said Force Majeure Event persists for longer than thirty (30) days, Testing Entity shall have the option to terminate this Agreement, without penalty.

## [Intentionally left blank. Signature page follows.]

IN WITNESS WHEREOF, the undersigned have duly executed this Agreement, or have caused this Agreement to be duly executed on their behalf, as of the Effective Date.

Wichita State University:	Testing Entity:
By: Jusjeli	By:
Print Name: John S. Tomblin	Print Name:
Title: SVP Industry & Defense Programs	Title:
3.8.2021 Date:	Date:

### EXHIBIT A


### SCHEDULE FOR DELIVERY OF TEST RESULTS/DROP-OFF OPTIONS

Testing Entity may use any of the following methods to get specimens to the Lab for processing:

- 1. Daily drop off of specimens at the Lab (preferred and fastest method)
- 2. Return specimens via FedEx Express

Please note: if the Testing Entity uses FedEx Express Packing Services, test results will be delayed due to shipping timelines. For fastest turnaround on test analysis and results, the Testing Entity is encouraged to drop off specimens at the Lab daily.

The following table provides an estimate of when Testing Entity can expect to receive test results. Lab shall use reasonable efforts to report test results to Designed Persons and Testing Entity, if authorized, within the time allotments set forth below. However, Testing Entity acknowledges and agrees that in no event will Lab guarantee that test results will be reported within the time allotments below. In the event that test results are scheduled to be given on a holiday observed by the State of Kansas, the test results shall be expected on the following business day after the holiday.



## **Receive Test Results**

\* Results will be delivered the following week

**Drop Off Specimens** 

rev. 03.04.2021

### EXHIBIT B

#### FEE SCHEDULE

The parties agree, for so long as CARES Act funding is available to Lab from the State of Kansas for the purpose of providing testing to residents of the State of Kansas, that the testing of Designated Persons will be at no cost to the Testing Entity ("Kansas CARES Funds"). Lab will notify Testing Entity at least five (5) days in advance of the date when Lab will no longer be able to use Kansas CARES Funds for the testing of Designated Persons ("Expiration Date"). After the Expiration Date, Testing Entity shall compensate Lab pursuant to the fee schedule set forth below.

TEST BILLING RATE	
<ul> <li>Established Billing Rate: SALIVA, SalivaDirect<sup>™</sup>, No Extraction, PCR, Prevalence (One Target Test)</li> <li>Minimum order is one bundle of 50 SalivaDirect<sup>™</sup> specimen collection. Kit, transportation from Testing Entity to Lab, and test analysis and results reporting through secure patient portal.</li> <li>Cost of one bundle of 50 SalivaDirect<sup>™</sup> kits is \$3,842.50 (50 kits x \$76.85 each).</li> </ul>	\$76.85
<ul> <li>Established Billing Rate: SWABS, Thermo Fisher Full Extraction PCR (Three Target Test)</li> <li>Minimum order is one bundle of 50 TaqPath<sup>™</sup> specimen collection kit, transportation from Testing Entity to Lab, and test analysis and results reporting through secure patient portal.</li> <li>Cost of one bundle of 50 TaqPath<sup>™</sup> kits is \$4,887.50 (\$97.75 each).</li> </ul>	\$97.75

Note: Test Billing Rate is subject to change if costs increase or decrease